Send to

Choose Destination
See comment in PubMed Commons below
Biol Neonate. 1996;69(1):1-11.

Recombinant human interleukin-3 enhances the in vitro survival of mononuclear phagocytes from the peripheral blood of very low birth weight premature infants at birth.

Author information

Department of Pediatrics, State University of New York at Stony Brook 11794-8111, USA.


Interleukin 3 (IL-3) is a pluripotent hematopoietic growth factor that stimulates proliferation, differentiation, and function of multiple cell lineages. We examined the effects of recombinant human IL-3 (rhIL-3) on peripheral blood mononuclear cells (MNC) isolated from 18 premature human newborns with birth weights between 600 and 1,500 g at birth and at 2 and 4 weeks of age, from 7 full-term neonates, and from 26 normal adult volunteers. After 2 weeks in liquid culture, rhIL-3 treatment was associated with a six- to nine-fold increase in the survival of MNC from very low birth weight (VLBW) neonates. In the absence of rhIL-3, VLBW neonatal MNC exhibited a low survival rate. MNC from 6 of 7 full-term neonates responded similarly to rhIL-3 with an eight-fold increase in survival. In contrast, rhIL-3 showed only a 20-30% increase in the survival of adult MNC (p = NS). When analyzed by immunofluorescent microscopy using monoclonal antibodies to phenotypic markers characteristic of individual MNC lineages, 70-80% of the surviving VLBW neonatal MNC were mononuclear phagocytes, while 70-80% of the surviving adult MNC were T cells. Full-term MNC cultures displayed a population of cells with an intermediate phenotype. Following rhIL-3 treatment, surviving MNC from term neonates displayed 35% T cells and 53% mononuclear phagocytes which was not significantly different from untreated MNC. rhIL-3 treatment was associated with a seven- to twelve-fold increase in the number of progenitor cells (CD34+) from VLBW neonatal blood and a three- to five-fold increase in the number of adult progenitor cells. Full-term neonates had a lower percentage of CD34+ cells than VLBW neonates, and this was not significantly altered by the rhIL-3 treatment. We conclude that rhIL-3 increases the number of mononuclear phagocytes that survive in culture following isolation from the peripheral blood of VLBW neonates. These in vitro studies may have a predictive value for in vivo studies utilizing combinations of hematopoietic growth factors to enhance neonatal host defense.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center